Review



tazemetostat  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    MedChemExpress tazemetostat
    <t>Tazemetostat</t> sensitizes PDAC cells to gemcitabine by upregulating the KLF15 expression ( A ) Cell viability analyses were performed in PANC-1-Vector, PANC-1-KLF15-OE, BxPC-3-Scramble and BxPC-3-KLF15-KD after Gemcitabine treatment. ( B ) Apoptotic cell analyses using flow cytometry were performed in PANC-1-Vector, PANC-1-KLF15-OE, BxPC-3-Scramble and BxPC-3-KLF15-KD after Gemcitabine treatment(left), and the proportion of apoptotic cells statistical analysis (right). * P < 0.05. (C-D) Western blot on the expression of H3K27me3, EZH2, KLF15 and Nanog after Tazemetostat treatment. (E-F) Q-PCR on the expression of KLF15 after treatment by different concentrations of Tazemetostat, GAPDH as the control. (G-H) ELDA for PANC-1 and SW1990 cells after Tazemetostat treatment, using the ELDA software ( http://bioinf.wehi.edu.au/software/elda ). All above experiments were repeated three times independently. Paired Student’s t-test was used for statistical analysis. * P < 0.05 ** P < 0.01*** P < 0.001. ( I ) The subcutaneous tumors formed by four groups: control, Tazemetostat, gemcitabine and the combination of Tazemetostat and gemcitabine, H&E staining and IHC staining of Ki67 in above four groups. (mean ± SD, n = 3), Scale bar (black), 200 μm. ( J ) The statistical analysis of Ki67 staining in the above four groups. (K-L) The volume ( K ) and the weight ( L ) of subcutaneous tumors in above four groups, (mean ± SD, n = 3), * P < 0.05 ** P < 0.01*** P < 0.001
    Tazemetostat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tazemetostat/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    tazemetostat - by Bioz Stars, 2026-03
    92/100 stars

    Images

    1) Product Images from "KLF15 suppresses stemness of pancreatic cancer by decreasing USP21-mediated Nanog stability"

    Article Title: KLF15 suppresses stemness of pancreatic cancer by decreasing USP21-mediated Nanog stability

    Journal: Cellular and Molecular Life Sciences: CMLS

    doi: 10.1007/s00018-024-05442-6

    Tazemetostat sensitizes PDAC cells to gemcitabine by upregulating the KLF15 expression ( A ) Cell viability analyses were performed in PANC-1-Vector, PANC-1-KLF15-OE, BxPC-3-Scramble and BxPC-3-KLF15-KD after Gemcitabine treatment. ( B ) Apoptotic cell analyses using flow cytometry were performed in PANC-1-Vector, PANC-1-KLF15-OE, BxPC-3-Scramble and BxPC-3-KLF15-KD after Gemcitabine treatment(left), and the proportion of apoptotic cells statistical analysis (right). * P < 0.05. (C-D) Western blot on the expression of H3K27me3, EZH2, KLF15 and Nanog after Tazemetostat treatment. (E-F) Q-PCR on the expression of KLF15 after treatment by different concentrations of Tazemetostat, GAPDH as the control. (G-H) ELDA for PANC-1 and SW1990 cells after Tazemetostat treatment, using the ELDA software ( http://bioinf.wehi.edu.au/software/elda ). All above experiments were repeated three times independently. Paired Student’s t-test was used for statistical analysis. * P < 0.05 ** P < 0.01*** P < 0.001. ( I ) The subcutaneous tumors formed by four groups: control, Tazemetostat, gemcitabine and the combination of Tazemetostat and gemcitabine, H&E staining and IHC staining of Ki67 in above four groups. (mean ± SD, n = 3), Scale bar (black), 200 μm. ( J ) The statistical analysis of Ki67 staining in the above four groups. (K-L) The volume ( K ) and the weight ( L ) of subcutaneous tumors in above four groups, (mean ± SD, n = 3), * P < 0.05 ** P < 0.01*** P < 0.001
    Figure Legend Snippet: Tazemetostat sensitizes PDAC cells to gemcitabine by upregulating the KLF15 expression ( A ) Cell viability analyses were performed in PANC-1-Vector, PANC-1-KLF15-OE, BxPC-3-Scramble and BxPC-3-KLF15-KD after Gemcitabine treatment. ( B ) Apoptotic cell analyses using flow cytometry were performed in PANC-1-Vector, PANC-1-KLF15-OE, BxPC-3-Scramble and BxPC-3-KLF15-KD after Gemcitabine treatment(left), and the proportion of apoptotic cells statistical analysis (right). * P < 0.05. (C-D) Western blot on the expression of H3K27me3, EZH2, KLF15 and Nanog after Tazemetostat treatment. (E-F) Q-PCR on the expression of KLF15 after treatment by different concentrations of Tazemetostat, GAPDH as the control. (G-H) ELDA for PANC-1 and SW1990 cells after Tazemetostat treatment, using the ELDA software ( http://bioinf.wehi.edu.au/software/elda ). All above experiments were repeated three times independently. Paired Student’s t-test was used for statistical analysis. * P < 0.05 ** P < 0.01*** P < 0.001. ( I ) The subcutaneous tumors formed by four groups: control, Tazemetostat, gemcitabine and the combination of Tazemetostat and gemcitabine, H&E staining and IHC staining of Ki67 in above four groups. (mean ± SD, n = 3), Scale bar (black), 200 μm. ( J ) The statistical analysis of Ki67 staining in the above four groups. (K-L) The volume ( K ) and the weight ( L ) of subcutaneous tumors in above four groups, (mean ± SD, n = 3), * P < 0.05 ** P < 0.01*** P < 0.001

    Techniques Used: Expressing, Plasmid Preparation, Flow Cytometry, Western Blot, Control, Software, Staining, Immunohistochemistry



    Similar Products

    tazemetostat  (MedChemExpress)
    92
    MedChemExpress tazemetostat
    <t>Tazemetostat</t> sensitizes PDAC cells to gemcitabine by upregulating the KLF15 expression ( A ) Cell viability analyses were performed in PANC-1-Vector, PANC-1-KLF15-OE, BxPC-3-Scramble and BxPC-3-KLF15-KD after Gemcitabine treatment. ( B ) Apoptotic cell analyses using flow cytometry were performed in PANC-1-Vector, PANC-1-KLF15-OE, BxPC-3-Scramble and BxPC-3-KLF15-KD after Gemcitabine treatment(left), and the proportion of apoptotic cells statistical analysis (right). * P < 0.05. (C-D) Western blot on the expression of H3K27me3, EZH2, KLF15 and Nanog after Tazemetostat treatment. (E-F) Q-PCR on the expression of KLF15 after treatment by different concentrations of Tazemetostat, GAPDH as the control. (G-H) ELDA for PANC-1 and SW1990 cells after Tazemetostat treatment, using the ELDA software ( http://bioinf.wehi.edu.au/software/elda ). All above experiments were repeated three times independently. Paired Student’s t-test was used for statistical analysis. * P < 0.05 ** P < 0.01*** P < 0.001. ( I ) The subcutaneous tumors formed by four groups: control, Tazemetostat, gemcitabine and the combination of Tazemetostat and gemcitabine, H&E staining and IHC staining of Ki67 in above four groups. (mean ± SD, n = 3), Scale bar (black), 200 μm. ( J ) The statistical analysis of Ki67 staining in the above four groups. (K-L) The volume ( K ) and the weight ( L ) of subcutaneous tumors in above four groups, (mean ± SD, n = 3), * P < 0.05 ** P < 0.01*** P < 0.001
    Tazemetostat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tazemetostat/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    tazemetostat - by Bioz Stars, 2026-03
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Tazemetostat sensitizes PDAC cells to gemcitabine by upregulating the KLF15 expression ( A ) Cell viability analyses were performed in PANC-1-Vector, PANC-1-KLF15-OE, BxPC-3-Scramble and BxPC-3-KLF15-KD after Gemcitabine treatment. ( B ) Apoptotic cell analyses using flow cytometry were performed in PANC-1-Vector, PANC-1-KLF15-OE, BxPC-3-Scramble and BxPC-3-KLF15-KD after Gemcitabine treatment(left), and the proportion of apoptotic cells statistical analysis (right). * P < 0.05. (C-D) Western blot on the expression of H3K27me3, EZH2, KLF15 and Nanog after Tazemetostat treatment. (E-F) Q-PCR on the expression of KLF15 after treatment by different concentrations of Tazemetostat, GAPDH as the control. (G-H) ELDA for PANC-1 and SW1990 cells after Tazemetostat treatment, using the ELDA software ( http://bioinf.wehi.edu.au/software/elda ). All above experiments were repeated three times independently. Paired Student’s t-test was used for statistical analysis. * P < 0.05 ** P < 0.01*** P < 0.001. ( I ) The subcutaneous tumors formed by four groups: control, Tazemetostat, gemcitabine and the combination of Tazemetostat and gemcitabine, H&E staining and IHC staining of Ki67 in above four groups. (mean ± SD, n = 3), Scale bar (black), 200 μm. ( J ) The statistical analysis of Ki67 staining in the above four groups. (K-L) The volume ( K ) and the weight ( L ) of subcutaneous tumors in above four groups, (mean ± SD, n = 3), * P < 0.05 ** P < 0.01*** P < 0.001

    Journal: Cellular and Molecular Life Sciences: CMLS

    Article Title: KLF15 suppresses stemness of pancreatic cancer by decreasing USP21-mediated Nanog stability

    doi: 10.1007/s00018-024-05442-6

    Figure Lengend Snippet: Tazemetostat sensitizes PDAC cells to gemcitabine by upregulating the KLF15 expression ( A ) Cell viability analyses were performed in PANC-1-Vector, PANC-1-KLF15-OE, BxPC-3-Scramble and BxPC-3-KLF15-KD after Gemcitabine treatment. ( B ) Apoptotic cell analyses using flow cytometry were performed in PANC-1-Vector, PANC-1-KLF15-OE, BxPC-3-Scramble and BxPC-3-KLF15-KD after Gemcitabine treatment(left), and the proportion of apoptotic cells statistical analysis (right). * P < 0.05. (C-D) Western blot on the expression of H3K27me3, EZH2, KLF15 and Nanog after Tazemetostat treatment. (E-F) Q-PCR on the expression of KLF15 after treatment by different concentrations of Tazemetostat, GAPDH as the control. (G-H) ELDA for PANC-1 and SW1990 cells after Tazemetostat treatment, using the ELDA software ( http://bioinf.wehi.edu.au/software/elda ). All above experiments were repeated three times independently. Paired Student’s t-test was used for statistical analysis. * P < 0.05 ** P < 0.01*** P < 0.001. ( I ) The subcutaneous tumors formed by four groups: control, Tazemetostat, gemcitabine and the combination of Tazemetostat and gemcitabine, H&E staining and IHC staining of Ki67 in above four groups. (mean ± SD, n = 3), Scale bar (black), 200 μm. ( J ) The statistical analysis of Ki67 staining in the above four groups. (K-L) The volume ( K ) and the weight ( L ) of subcutaneous tumors in above four groups, (mean ± SD, n = 3), * P < 0.05 ** P < 0.01*** P < 0.001

    Article Snippet: One week later, Gemcitabine (20 mg/kg/day, DMSO was used as control, MCE, HY-17026) was injected once a week, and Tazemetostat (100 mg/kg, DMSO was used as control, MCE, HY-147090) was injected three times a week.

    Techniques: Expressing, Plasmid Preparation, Flow Cytometry, Western Blot, Control, Software, Staining, Immunohistochemistry